Τίτλος:
The recent progress in RSV vaccine technology
Γλώσσες Τεκμηρίου:
Αγγλικά
Περίληψη:
The most effective way to control RSV infection would be the development of an expedient and safe vaccine. Subunit vaccines, live attenuated RSV vaccines, plasmid DNA vaccines have been tested either in human or in mouse models without reaching the ultimate goal of efficacy and safety, at least in humans. Viruses such as adenovirus, sendai virus, measles virus were also used as vectors for the generation of RSV vaccines with promising results in animal models. Recent patents describe new techniques for the generation of candidate vaccines. These patents include virus like particles as vaccine platforms, recombinant RSVs or modified RSV F protein as component of the vaccine. Despite the number of the candidate vaccines, the new RSV vaccines should overcome many obstacles before being established as effective vaccines for the control of RSV infections especially for the young infants who are more susceptible to the virus. © 2012 Bentham Science Publishers.
Συγγραφείς:
Fretzayas, A.
Papadopoulou, A.
Kotzia, D.
Moustaki, M.
Περιοδικό:
Recent Patents on Anti-Infective Drug Discovery
Λέξεις-κλειδιά:
adenovirus vaccine; DNA vaccine; immunoglobulin G; interleukin 13; interleukin 2; interleukin 5; live vaccine; respiratory syncytial virus vaccine; toll like receptor 2; toll like receptor 4; virus protein, antibody detection; antibody titer; article; codon; disease predisposition; drug efficacy; drug research; drug safety; human; immunization; immunogenicity; immunoglobulin blood level; immunopathology; nonhuman; patent; priority journal; protein domain; respiratory syncytial virus infection; signal transduction; Th1 cell; Th2 cell; viral clearance; virus capsid; virus neutralization; virus nucleocapsid; virus replication; virus shedding, Animals; Humans; Respiratory Syncytial Virus Infections; Respiratory Syncytial Virus Vaccines; Respiratory Syncytial Virus, Human
DOI:
10.2174/157489112803522002
